alexa 6-thioguanine In Vivo Selection For Hematopoietic Stem Cell Transplantation (HSCT)
ISSN: 2155-9864

Journal of Blood Disorders & Transfusion
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading Please wait..

3rd International Conference on Hematology & Blood Disorders
November 02-04, 2015 Atlanta, USA

Robert H Schiestl
University of California, USA
Keynote: J Blood Disord Transfus
DOI: 10.4172/2155-9864.C1.009
Hematopoietic stem cell transplantation (HSCT) is often the only/last treatment option of some malignancies, congenital diseases and bone marrow failure. For efficient engraftment of donor HSC’s stem cell niches have to be provided. Here we developed an in vivo selection scheme for HSCT based on the fact that 6-thioguanine (6TG) toxicity is essentially predicated on its HPRT mediated conversion to thioguanine nucleotide and strongly myelosuppressive. At appropriate concentrations 6TG is strongly myeloablative with little toxicity to other tissues. Therefore it is possible to eliminate diseased bone marrow and replace it with healthy donor bone marrow that lacks HPRT. We have shown that only Hprt proficient cells are susceptible to 6-TG allowing selection in favor of Hprt deficient donor HSC’s in vivo and that a 4 week selection regimen results in a 95% replacement of the host’s marrow. Engraftment is more robust with 6-TG selection than with radiation. The proposed method offers selection through a less toxic compound (compared to other schemes) hence less side effects, use of smaller, siRNAproducing vectors (therefore potentially more efficient), possible use of non-integrating vectors and less patient discomfort. The general aim of this project is to show that HSC’s deficient for HPRT can be selected for in vivo through 6TG administration, that this procedure would be applicable for conditions like hematological malignancies, congenital diseases and bone marrow failure i.e., where HSCT is indicated and to test all aspects of this procedure to eventually allow for phase-1 clinical trials.

Robert H Schiestl has obtained his PhD from the University of Vienna. He was a Postdoctoral Fellow at Edmonton, Alberta, Rochester, NY and Chapel Hill, NC before being Professor at Harvard where he stayed for 10 years. Since 15 years he is a Professor at UCLA with 187 publications, 10 patents and 2 startup companies.

Email: [email protected]

image PDF   |   image HTML

Relevant Topics

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version